Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07293754 · ClinicalTrials.gov registry record · Phase 1
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
A Phase 1 study of Advanced Malignant Solid Tumor, sponsored by Repertoire Immune Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT07293754 is a Phase 1 study of Advanced Malignant Solid Tumor that is actively recruiting participants, run by Repertoire Immune Medicines. The registered enrollment target is 150 participants, above the 34-participant average among 3 other Advanced Malignant Solid Tumor trials with a reported enrollment target (341% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07293754, a Phase 1 study of Advanced Malignant Solid Tumor, is actively recruiting participants, sponsored by Repertoire Immune Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.
Conditions Studied
Interventions
- DRUG RPTR-1-201
- DRUG PD-1 / PD-L1 monoclonal antibody
Study Locations (1)
Michigan
- START Midwest - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2029-04-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07293754
The ClinicalTrials.gov registry entry for NCT07293754 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 3 other Advanced Malignant Solid Tumor trials with a reported enrollment target (341% higher). The listed sponsor is Repertoire Immune Medicines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Malignant Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which RPTR-1-201 is the first listed.
NCT07293754 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT07293754 about?
NCT07293754 is a clinical study titled "An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors". This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-P...
What is the current status of trial NCT07293754?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-12-12. Estimated completion is 2029-04-15.
What conditions does trial NCT07293754 study?
This clinical trial studies the following conditions: Advanced Malignant Solid Tumor.
What interventions are being tested in trial NCT07293754?
The interventions under investigation include: RPTR-1-201 (DRUG), PD-1 / PD-L1 monoclonal antibody (DRUG).
Who is sponsoring clinical trial NCT07293754?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07293754 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Malignant Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
RECRUITING · Phase 1
-
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.